ALUMIS INC.
ALMSDrugs in Pipeline
3
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How ALMS's past catalysts played out
Open-Label ESK-001
Plaque Psoriasis
ESK-001
Plaque Psoriasis
Apremilast
Plaque Psoriasis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Open-Label ESK-001 | Phase 3 | Plaque Psoriasis | - | - |
ESK-001 | Phase 3 | Plaque Psoriasis | - | - |
Apremilast | Phase 3 | Plaque Psoriasis | - | - |
Frequently asked questions
What is in ALUMIS INC.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in ALUMIS INC.'s (ALMS) pipeline across Phase 3. Its lead program is Open-Label ESK-001 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ALUMIS INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for ALUMIS INC. (ALMS) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ALMS biotech catalysts?→
Add ALMS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ALUMIS INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.